An enduring principle for successful intervention in human disease is to identify - and then prevent - the earliest steps in pathogenesis. In the case of Alzheimer's disease and its harbinger, mild cognitive impairment (MCI), studies from many labs support the still unproven hypothesis that the gradual accumulation and oligomerization of amyloid p-protein (AB) in brain regions serving memory and cognition initiates this complex syndrome. Given the enormous resources being expended by academic and pharmaceutical scientists to identify anti-amyloid therapies and bring them to human trials, it is crucial to understand precisely how soluble AB begins to oligomerize and whether this process actually induces the subtle compromise of synaptic function seen in MCI and early AD. In this new RO1 application, investigators who have collaborated productively to discover the natural secretion of low-n AB oligomers in cell culture and then demonstrate their ability to inhibit long-term potentiation and disrupt memory in living animals now propose to rigorously define at the molecular level these earliest AB assembly forms and elucidate their mechanisms of action on neuronal function. Based on extensive preliminary data and sensitive biochemical methods we have developed to isolate and study natural oligomers, we propose 4 interrelated Specific Aims. 1. Determine the precise molecular composition of naturally secreted AB oligomers by mass spectrometry and search for covalent crosslinks, associated small molecules and/or binding proteins that may contribute to their potent neuronal activity. 2. Characterize the effects of the natural oligomers on synaptic form and function, including in organotypic hippocampal cultures, and assess whether they can induce AD-type tau phosphorylation and altered transmitter release in vivo, 3. Purify the natural oligomers to homogeneity, intrinsically label them and identify their cognate molecular and cellular targets in living brain. 4. Assess 3 specific therapeutic strategies to decrease the production of cell-secreted oligomers and thereby abrogate their synaptotoxicity: (B- or y-secretase inhibitors; certain anti-aggregation compounds; and chaperone expression. Our extensive experience in studying this unlimited cellular source of physiological amounts of human AB oligomers should enable us to exploit this unique experimental paradigm to elucidate both the nature and the neuronal effects of the earliest AB assemblies, with attendant therapeutic implications. Relevance to Public Health: Because our central hypothesis is that the earliest-forming """"""""oligomers"""""""" (doublets, triplets, etc.) of amyloid B-protein underlie the subtle and progressive impairment of memory that is the hallmark of incipient AD, we will use a unique experimental system in which cultured cells naturally produce such early forms in order to decipher the precise nature of these pathogenic assemblies, identify their mechanism of injury on the neurons and synapses required for memory, and then block this process with novel drugs. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG027443-01
Application #
7027342
Study Section
Neurodegeneration and Biology of Glia Study Section (NDBG)
Program Officer
Snyder, Stephen D
Project Start
2006-04-01
Project End
2011-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
1
Fiscal Year
2006
Total Cost
$441,847
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Lei, Ming; Xu, Huixin; Li, Zhangyuan et al. (2016) Soluble A? oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance. Neurobiol Dis 85:111-121
Mc Donald, Jessica M; O'Malley, Tiernan T; Liu, Wen et al. (2015) The aqueous phase of Alzheimer's disease brain contains assemblies built from ?4 and ?7 kDa A? species. Alzheimers Dement 11:1286-305
Jin, Ming; Selkoe, Dennis J (2015) Systematic analysis of time-dependent neural effects of soluble amyloid ? oligomers in culture and in vivo: Prevention by scyllo-inositol. Neurobiol Dis 82:152-163
Hong, Soyon; Ostaszewski, Beth L; Yang, Ting et al. (2014) Soluble A? oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82:308-19
Li, Shaomin; Jin, Ming; Zhang, Dainan et al. (2013) Environmental novelty activates ?2-adrenergic signaling to prevent the impairment of hippocampal LTP by A? oligomers. Neuron 77:929-41
Yang, Ting; Hong, Soyon; O'Malley, Tiernan et al. (2013) New ELISAs with high specificity for soluble oligomers of amyloid ?-protein detect natural A? oligomers in human brain but not CSF. Alzheimers Dement 9:99-112
McDonald, Jessica M; Cairns, Nigel J; Taylor-Reinwald, Lisa et al. (2012) The levels of water-soluble and triton-soluble A? are increased in Alzheimer's disease brain. Brain Res 1450:138-47
O'Nuallain, Brian; Klyubin, Igor; Mc Donald, Jessica M et al. (2011) A monoclonal antibody against synthetic Aýý dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aýý. J Neurochem 119:189-201
Freir, Darragh B; Fedriani, Rocio; Scully, Darren et al. (2011) A? oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging 32:2211-8
Jin, Ming; Shepardson, Nina; Yang, Ting et al. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108:5819-24

Showing the most recent 10 out of 24 publications